Kailera Therapeutics (KLRA) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros is the larger company by market cap ($1.38 billion vs $1.30 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRA | OMER |
|---|---|---|
| Share price | $10.00 | $19.12 |
| Market cap | $1.30B | $1.38B |
| 1-day change | -5.03% | +1.97% |
| YTD return | — | +9.14% |
| 1-year return | — | +322.30% |
| 5-year return | — | +142.56% |
| P/E ratio (TTM) | — | 15.67 |
| Forward P/E | — | 15.54 |
| EPS (TTM) | $-4.51 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $21.24 |
| 52-week low | $9.76 | $4.06 |
| Distance from 52-week high | -64.58% | -9.98% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +324.00% | +43.83% |
| Average volume | 848.03K | 1.74M |
| Shares outstanding | 129.64M | 72.39M |
| Employees | 145 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
KLRA vs OMER FAQ
Which is bigger, Kailera Therapeutics or Omeros?
Omeros (OMER) is larger, with a market capitalization of $1.38B compared with $1.30B for Kailera Therapeutics (KLRA).
Are Kailera Therapeutics and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.